SCHEMBL17218433

SCHEMBL17218433

CC[C]=NOCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.49
MAOB P27338 7/20 0.45
KMT2A Q03164 2/20 0.42
MIF P14174 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
PYCR1 P32322 1/20 0.37
FFAR1 O14842 1/20 0.37
NAAA Q02083 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
S1PR1 P21453 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17218430 1.00 IDO1 (0.49) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17219669 0.87 IDO1 (0.46) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17219670 0.87 IDO1 (0.46) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17986250 0.86 IDO1 (0.52) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17986251 0.86 IDO1 (0.52) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17216493 0.84 IDO1 (0.44) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17216491 0.84 IDO1 (0.44) IDO1MAOBKMT2AMIFTAAR1
SCHEMBL17217523 0.81 IDO1 (0.54) IDO1MAOBMIFTAAR1
SCHEMBL17217521 0.81 IDO1 (0.54) IDO1MAOBMIFTAAR1
SCHEMBL17216166 0.81 IDO1 (0.44) IDO1MAOBKMT2AMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 EP disclosed
US-9635857-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-02 US disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 US disclosed
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-18 US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF MRPS17, TAOK1, TAOK3 IDO1 1822/4885MAOB 2207/4885KMT2A 3920/4885
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885MAOB 3611/4885KMT2A 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.